Pyrimethamine Treatment Market Research Report Forecast to 2023

Pyrimethamine is a medication used for protozoan infections. It is commonly used as an antimalarial drug (for both treatment and prevention of malaria), and to treat Toxoplasma gondii infections, particularly when combined with the sulfonamide antibiotic sulfadiazine when treating HIV-positive individuals. Pyrimethamine is typically given with a sulfonamide and folinic acid due to its resistance against many Plasmodium species. Pyrimethamine has also been found to limit the expression of the superoxide dismutase 1 gene, a protein involved in amyotrophic lateral sclerosis. Pyrimethamine is considered in the list of one of the most important medications by World Health Organization’s list of essential medicines. Pyrimethamine’s ability to cure protozoan infection and toxoplasma infections, rising number of HIV positive patients worldwide and immunosuppressed individual at a risk of infections are the factors driving the pyrimethamine treatment market during the forecast period. Moreover, mergers and acquisitions by the manufacturing companies would also the boost the demand and supply for the pyrimethamine medication in the pyrimethamine treatment market. However, the certain side effects that may occur with pyrimethamine medication include allergic reactions, blood disorders, tongue changes, blood in the urine, heart rhythm disorders, anorexia, and vomiting (see Important Safety Information below) which act as a restraining factor for the growth of this market. Additionally, factors such as pricing issues in some countries and resistance developing against the drugs may hamper the growth of the pyrimethamine treatment market during the focus period of 2013 to 2023.

This report gives readers a comprehensive overview of the Pyrimethamine Treatment Market:
http://www.transparencymarketresearch.com/pyrimethamine-treatment-market.html

The global pyrimethamine market has been segmented into brands and geography. On the basis of brand, the pyrimethamine treatment market has been segmented into two drugs that are presently marketed such as Daraprim and Fansidar. The Daraprim sub-segment held the largest share for the pyrimethamine treatment market. However, the Fansidar sub-segment is growing at a high rate due to affordable cost and availability.

Get accurate market forecast and analysis on the Pyrimethamine Treatment Market. Request a sample to stay abreast on the key trends impacting this market: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=8170

Geographically, North America dominates the global pyrimethamine treatment market followed by Europe. The market domination was majorly due to the pricing structure of the pyrimethamine drug in the U.S. The High prevalence of toxoplasma in the region also acts as the driving factor for the growth of the pyrimethamine treatment in the North America. According to The Centers for Disease Control and Prevention (CDC), toxoplasmosis is one of the five neglected parasitic infections in the U.S. It is the second leading cause of death from foodborne illness in the country and more than 60 million people in the U.S. carry the toxoplasma parasite, and more than one million people in the U.S. are infected annually with the toxoplasma parasite, which is associated with high rates of morbidity and mortality. Asia-Pacific is also increasing constantly in the pyrimethamine drugs market mainly due to the high prevalence of protozoan disease such as malaria in India, China and other developing nations. Moreover, government initiatives and regulatory norms in these countries would fuel the market for pyrimethamine treatment market in the region during the forecast period. Latin America is also a growing market for pyrimethamine treatment due to developing healthcare expenditure and high prevalence rate of malaria and toxoplasma in the region.

Some of the major players in pyrimethamine treatment market include Turing Pharmaceuticals, Impax Laboratories, Inc., Pfizer, Inc. GlaxoSmithKline plc, and others.

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Each TMR syndicated research report covers a different sector - such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.

Contact us:

Transparency Market Research
90 State Street,
Suite 700,
Albany
NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/

This release was published on openPR.